Project Grant R01AI192378
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $792K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop a multivalent mRNA HIV vaccine that can elicit broadly neutralizing antibodies targeting the conserved envelope (Env) region of recently circulating subtype C HIV strains. The central hypothesis is that priming with a single Env immunogen followed by boosting with a multivalent Env immunogen set...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...
- This federal Project Grant award of $4,630,686 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop an effective HIV vaccine. The primary goal is to stimulate B cell lineages capable of producing broadly neutralizing antibodies (bnAbs) against diverse HIV strains, a key challenge in traditional vaccine approaches. The research involves preclinical studies in non-human primates using the BG505...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $910,905 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, CA. The grant, awarded on July 1, 2025, supports the development of an HIV vaccine using a lipid nanodisc platform to incorporate the envelope (Env) glycoprotein of HIV. The project aims to enable scalable and reproducible in vitro characterization and optimization of engineered...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,285,304 to the Scripps Research Institute to conduct research on developing a durable broadly neutralizing antibody (bnAb) response for an HIV vaccine. The key objectives are to: Assess the durability of a 6-shot sequential vaccine regimen that induces bnAb responses in non-human primates. Evaluate the...
- This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $1,239,565.00 to Duke University to conduct research on the mechanisms of early-life immunity associated with HIV-1 vaccine-induced neutralizing antibody responses. The research aims to understand the permissive immunological environment for vaccine-induced broadly neutralizing antibody development in infants and children, a key gap...
- This Project Grant award of $800,389.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The proposed treatment combines soluble IL-15/IL-15RA-FC with a TGF-β pathway blockade and therapeutic vaccination to enhance and restore anti-viral immunity, leading to sustained viral remission...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,017,032 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the Scripps Research Institute. The grant supports research to develop a single-shot sequential immunization regimen for HIV using atomic layer deposition (ALD) technology. The project aims to create a vaccine capable of eliciting broadly neutralizing antibodies (bNAbs) to provide effective protection...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $7,105,240 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program to the University of California, Davis. This funding will support a collaborative HIV vaccine research program, referred to as OPTI-FLIP, that aims to develop a vaccine regimen leveraging cooperative interactions between antibody and T-cell immune responses. The key research activities funded under this grant...
- The University of Pennsylvania received a $891,410 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on therapeutic vaccination strategies to boost autologous neutralizing antibodies for ART-free HIV control. The award is focused on testing whether individualized mRNA-LNP delivered Env immunogens can enhance baseline autologous neutralizing antibody responses...